EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interleukin-38 Ameliorates Atherosclerosis by Inhibiting Macrophage M1-like Polarization and Apoptosis

Zhiyang Li iD, Xuelian Li, Rui Shen, Yue Wang, Jian Yu, Chengliang Pan, Yifan Cai, Qian Dong, Kunwu Yu, Qiutang Zeng iD

Biomolecules · 2025

DOI: 10.3390/biom15121741 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Zhiyang Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Hauptthemen laut MEDLINE: Apoptosis, Interleukins, Atherosclerosis, Macrophages. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

As a novel member of the interleukin(IL)-1 family, IL-38 has shown therapeutic effects in various chronic inflammatory diseases. However, its role and underlying mechanisms in cardiovascular diseases, particularly atherosclerosis, remain unclear. This study aimed to explore the effects of IL-38 on atherosclerosis progression and its mechanisms in regulating macrophage function during the atherosclerotic process.

Methods

To evaluate the therapeutic potential of IL-38 in atherosclerosis, we performed histopathological examinations and biochemical analyses in vivo. In vitro, we used primary bone marrow-derived macrophages (BMDMs) stimulated with oxidized low-density lipoprotein (ox-LDL) to assess the anti-inflammatory effects of IL-38 and quantified its impact on ox-LDL-induced macrophage polarization. To further elucidate the specific mechanisms by which IL-38 regulates macrophage function, we conducted mRNA sequencing and validated downstream regulatory signaling pathways.

Results

IL-38 exhibited therapeutic potential in atherosclerosis by reducing atherosclerotic plaque formation, modulating plaque composition, suppressing the production of proinflammatory cytokines within plaques, and potentially regulating macrophage cholesterol metabolism. Moreover, IL-38 exerted significant anti-inflammatory effects on macrophages both in vivo and in vitro. Notably, it inhibited the polarization of macrophages toward the proinflammatory M1-like phenotype in both settings. Additionally, IL-38 impeded the phosphorylation and nuclear translocation of p65 in BMDMs and reduced ox-LDL-induced macrophage apoptosis.

Conclusion

IL-38 holds therapeutic potential for atherosclerosis, as it alleviates disease progression, inhibits macrophage polarization toward the M1-like phenotype, suppresses nuclear factor-κB (NF-κB) signaling activation, and reduces macrophage apoptosis. This study provides new insights into the anti-inflammatory mechanisms by which IL-38 mitigates atherosclerosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisInterleukinsAtherosclerosisMacrophagesMaleAnimalsMiceMice, Inbred C57BLMice, KnockoutApolipoproteins ECholesterolInflammationSignal TransductionNF-kappa B

Stichwörter der Autor:innen

Interleukin-38atherosclerosisinflammationmacrophage

Substanzen

InterleukinsApoe protein, mouseApolipoproteins ECholesterolNF-kappa B

Autor:innen und Institutionen

  • Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • Key Laboratory of Biological Targeted Therapy, Ministry of Education, Huazhong University of Science and Technology, Wuhan 430022, China.

ORCID-Profile: Zhiyang Li, Qiutang Zeng

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, Z., Li, X., Shen, R., Wang, Y., Yu, J., Pan, C., Cai, Y., Dong, Q., Yu, K., & Zeng, Q. (2025). Interleukin-38 Ameliorates Atherosclerosis by Inhibiting Macrophage M1-like Polarization and Apoptosis. Biomolecules. https://doi.org/10.3390/biom15121741

Vancouver

Li Z, Li X, Shen R, Wang Y, Yu J, Pan C, et al. Interleukin-38 Ameliorates Atherosclerosis by Inhibiting Macrophage M1-like Polarization and Apoptosis. Biomolecules. 2025. doi:10.3390/biom15121741

BibTeX
@article{Li2025,
  author = {Li, Zhiyang and Li, Xuelian and Shen, Rui and Wang, Yue and Yu, Jian and Pan, Chengliang and Cai, Yifan and Dong, Qian and Yu, Kunwu and Zeng, Qiutang},
  title = {Interleukin-38 Ameliorates Atherosclerosis by Inhibiting Macrophage M1-like Polarization and Apoptosis},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15121741}
}
Kostenlos starten →